Bischofberger's Kronos files for IPO to run pivotal cancer trial

Norbert Bischofberger’s Kronos Bio has filed to raise up to $100 million in a Nasdaq IPO. The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line acute myeloid leukemia (AML) drug licensed from Bischofberger's former employer Gilead.